HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Deals

Madrigal continues MASH deal spree with $1B biobucks license for Arrowhead asset rejected by J&J

Madrigal Pharmaceuticals has struck a backloaded deal for the global license to an Arrowhead Pharmaceuticals phase 1 asset for patients with metabolic dysfunction-associated steatohepatitis (MASH).

By FierceBiotech · May 6, 2026 · via FierceBiotech
Madrigal continues MASH deal spree with $1B biobucks license for Arrowhead asset rejected by J&J

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

Tags
dealsformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
MSD concludes Terns acquisition to expand CML pipeline
DealsPharmaceutical Technology ↗
MSD concludes Terns acquisition to expand CML pipeline
MSD has completed its acquisition of Terns Pharmaceuticals, expanding its pipeline of treatments for chronic m…
May 6, 2026
UCB inks $2B Candid buyout to join Gilead in autoimmune field
DealsFierceBiotech ↗
UCB inks $2B Candid buyout to join Gilead in autoimmune field
UCB has struck a deal to acquire Candid Therapeutics for $2 billion upfront, hijacking a planned reverse merge…
May 5, 2026
UCB bets $2B on Candid's T cell engager ambitions
DealsEndpoints News ↗
UCB bets $2B on Candid's T cell engager ambitions
Ken Song has done it again. The biopharma veteran's all-out effort to prove T cell engagers' potential in auto…
May 4, 2026